Mumuni A Momoh1 
,
Ossai C Emmanuel2-4,6,
Azubuike C Onyeto3,
Youngson Darlington1,
Franklin C Kenechukwu1,
Kenneth C Ofokansi1,
Anthony A Attama1
For correspondence:- Mumuni Momoh Email: audu.momoh@unn.edu.ng Tel:+2348037784357
Accepted: 17 April 2019 Published: 31 May 2019
Citation: Momoh MA, Emmanuel OC, Onyeto AC, Darlington Y, Kenechukwu FC, Ofokansi KC, et al. Preparation of snail cyst and PEG-4000 composite carriers via PEGylation for oral delivery of insulin: An in vitro and in vivo evaluation. Trop J Pharm Res 2019; 18(5):919-926 doi: 10.4314/tjpr.v18i5.2
© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To develop PEGylated mucin as a carrier system for oral insulin delivery.
Methods: Varied ratios of snail cyst were molecularly modified with polyethylene glycol 4000 (PEG 4000). Briefly, In each case, 20 g quantities of snail cyst and PEG 4000 were separately dispersed in distilled water, stirred and allowed to stand for 24 h to produce a homogeneous dispersion and clear solution, respectively. The solution of PEG was added to the snail cyst dispersion, stirred and allowed 12 h for molecular interaction. The mixture was added to a 250-mL beaker containing 100 mL of light liquid paraffin. The microparticles were obtained after stirring and removing the paraffin using chilled acetone. The obtained PEGylated mucin matrices, which were subsequently loaded with insulin using a diffusion method, characterized for particles size, drug loading, encapsulation efficiency, in vitro drug release and evaluated for oral application in diabetic rats.
Results: The polymer hybrids improved insulin encapsulation efficiency (max 82.3 %), gave. polydispersity indices that ranged from 0.11 ± 0.1 to 0.24 ± 0.2, zeta potential values between 28 ± 0.3 and 38 ± 1.1 mV. Insulin release was highest (68 % in 6 h) for batch C and was sustained for 10 h in simulated intestinal fluid. The optimized batch (C-5) showed higher hypoglycaemic activity (56.5 %) than control (0.5 %) in diabetic rats.
Conclusion: The results suggest that PEGylated mucin can potentially be developed as a platform for oral insulin delivery.
Archives
News Updates
Fulltext in PDF